Hsbc Holdings PLC Takes Position in AxoGen, Inc. $AXGN

Hsbc Holdings PLC acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN) during the 1st quarter, Holdings Channel reports. The firm acquired 23,007 shares of the medical equipment provider’s stock, valued at approximately $754,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Stephens Investment Management Group LLC bought a new position in shares of AxoGen during the 4th quarter valued at about $5,043,000. Legato Capital Management LLC purchased a new position in shares of AxoGen in the 4th quarter worth approximately $1,323,000. SG Americas Securities LLC increased its position in AxoGen by 459.9% during the fourth quarter. SG Americas Securities LLC now owns 65,480 shares of the medical equipment provider’s stock valued at $2,143,000 after acquiring an additional 53,786 shares during the last quarter. F&V Capital Management LLC bought a new position in AxoGen during the 4th quarter valued at about $5,793,000. Finally, TimesSquare Capital Management LLC bought a new position in shares of AxoGen during the fourth quarter valued at approximately $11,025,000. Institutional investors own 80.29% of the company’s stock.

Insiders Place Their Bets

In related news, Director Kathy Johnson Weiler sold 16,344 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy Mcbride Wendell sold 1,647 shares of AxoGen stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $42.60, for a total transaction of $70,162.20. Following the completion of the sale, the director owned 93,826 shares in the company, valued at approximately $3,996,987.60. This trade represents a 1.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 29,041 shares of company stock worth $1,268,792. Company insiders own 2.44% of the company’s stock.

AxoGen Trading Up 0.5%

Shares of NASDAQ:AXGN opened at $41.37 on Thursday. The company has a current ratio of 7.10, a quick ratio of 5.33 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $2.20 billion, a PE ratio of -64.64 and a beta of 1.09. The business has a 50 day moving average of $42.10 and a two-hundred day moving average of $37.28. AxoGen, Inc. has a 12-month low of $12.39 and a 12-month high of $46.95.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.12. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. The firm had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. As a group, analysts forecast that AxoGen, Inc. will post -0.37 EPS for the current year.

AxoGen News Summary

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Revenue exceeded expectations: AxoGen reported second-quarter 2026 revenue of $69.73 million, above the $67.10 million analyst consensus. The result indicates continued demand for the company’s peripheral nerve repair products. AxoGen Second-Quarter 2026 Financial Results
• Positive Sentiment: Adjusted earnings beat some estimates: AxoGen reported quarterly EPS of $0.12, matching the consensus cited by MarketBeat and exceeding the $0.09 estimate tracked by Zacks. EPS was also unchanged from the year-earlier quarter. AxoGen Tops Q2 Earnings and Revenue Estimates
• Neutral Sentiment: Management updated fiscal 2026 guidance: The company provided an updated earnings outlook, but the supplied report does not include a numerical EPS target, limiting the ability to assess whether the revision is favorable. AxoGen Q2 2026 Earnings Call Highlights
• Negative Sentiment: Margins remain a concern: Earnings coverage characterized the quarter as strong on revenue but challenged by margins. AxoGen continues to report a negative net margin of 13.21% and negative return on equity of 9.63%, highlighting ongoing pressure to convert sales growth into sustainable profitability. AxoGen Q2 2026 Earnings Call Transcript

Analyst Ratings Changes

Several research analysts recently commented on AXGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research note on Friday, May 29th. Citigroup reaffirmed an “outperform” rating on shares of AxoGen in a research report on Wednesday, April 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of AxoGen in a research report on Wednesday, April 29th. Lake Street Capital upped their target price on AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Finally, Citizens Jmp upped their price target on shares of AxoGen from $42.00 to $50.00 and gave the company a “market outperform” rating in a research note on Wednesday, April 29th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AxoGen currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.88.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.